Open an account

Athersys

ATHXQ · OTC

$0.00+$0.00 (+0.00%)TodayMarket closed ·
No price history for this range.

About ATHXQ

Athersys, Inc. is a biotechnology company, which focuses on the field of regenerative medicine. The company is headquartered in Cleveland, Ohio and currently employs 24 full-time employees. The company went IPO on 2007-04-23. The firm's MultiStem cell therapy, a patented and proprietary allogeneic off-the-shelf stem cell product, is its lead platform product for treating indications in the neurological, inflammatory and immune, and cardiovascular disease areas, as well as certain other critical care conditions. MultiStem is being evaluated in several clinical-stage programs. Its advanced program is focused on the treatment of ischemic stroke, which is being evaluated in a registrational trial in Japan, and in a Phase III clinical trial primarily in North America and Europe under a Special Protocol Assessment (SPA). Its clinical development programs are focused on treating neurological conditions, inflammatory and immune disorders, cardiovascular disease, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients.

Employees
24
Headquarters
CLEVELAND, Ohio
Listed
Apr 23, 2007
Sector
Health Care
Industry
Biotechnology
Website
athersys.com

ATHXQ key statistics

Market cap
62
Price-earnings ratio
-0.00
Dividend yield
—
Average volume
12.00K
Volume
64
Open price
$0.00
High today
$0.0034
Low today
$0.00
52 Week high
$0.0034
52 Week low
$0.00

Athersys (ATHXQ) at a glance

As of Oct 16, 2026, Athersys (ATHXQ) shares are priced at $0.00, giving the company a market cap of 62 and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.00 and $0.0034. The current price is 0.0% above the day's low and 100.0% below its high.

Volume so far is 64 shares, below the average of 12.00K shares a day.

Over the past year Athersys has ranged from $0.00 to $0.0034, and now sits 0% of the way up that range.

Athersys met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q3 FY23 it reported -$0.15 per share against an estimate of -$0.2163.

ATHXQ earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 22.2% on average.

  1. Q4 FY21: reported -$2.25 per share against an estimate of -$1.93
  2. Q1 FY22: reported -$2.25 per share against an estimate of -$2.49
  3. Q2 FY22: reported -$2.25 per share against an estimate of -$1.80
  4. Q3 FY22: reported -$1.15 per share against an estimate of -$2.02
  5. Q4 FY22: reported -$0.83 per share against an estimate of -$0.8755
  6. Q1 FY23: reported -$0.43 per share against an estimate of -$0.5562
  7. Q2 FY23: reported -$0.62 per share against an estimate of -$0.2987
  8. Q3 FY23: reported -$0.15 per share against an estimate of -$0.2163

Similar companies

Companies in the same industry as Athersys

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.